Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06995820 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.

A Phase 1 study of Healthy, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
136
Enrollment target
1
Study location

NCT06995820 is a Phase 1 study of Healthy that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 136 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06995820, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
136 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AZD1613 in healthy participants, including Japanese and Chinese descent.

Conditions Studied

Healthy

Interventions

  • DRUG Placebo
  • DRUG AZD1613

Study Locations (1)

California

  • Research Site - Glendale

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2025-06-06
Est. Completion 2026-09-23
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06995820

The ClinicalTrials.gov registry entry for NCT06995820 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (79% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06995820 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06995820 about?

NCT06995820 is a clinical study titled "A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.". The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AZD1613 in healthy participants, including Japanese and Chinese descent.

What is the current status of trial NCT06995820?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2025-06-06. Estimated completion is 2026-09-23.

What conditions does trial NCT06995820 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT06995820?

The interventions under investigation include: Placebo (DRUG), AZD1613 (DRUG).

Who is sponsoring clinical trial NCT06995820?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06995820 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.